Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00335478
Other study ID # CDR0000476568
Secondary ID OHSU-CPC-05052-L
Status Completed
Phase Phase 2
First received June 8, 2006
Last updated May 7, 2017
Start date December 2006
Est. completion date October 2008

Study information

Verified date May 2017
Source OHSU Knight Cancer Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

RATIONALE: Antibiotics, such as daptomycin, may control neutropenia, fever, and infection in patients with cancer.

PURPOSE: This phase II trial is studying how well daptomycin works in treating neutropenia and fever in patients with cancer.


Description:

OBJECTIVES:

Primary

- Assess the response rate to therapy within 72 hours of starting daptomycin in cancer patients with neutropenic fever.

Secondary

- Assess the percentage of bacterial cures in patients with documented gram-positive bacterial infections.

- Assess time to afebrile state.

- Assess the pharmacokinetic data of daptomycin in neutropenic patients.

- Document the incidence of breakthrough infections that require a change of therapy or additional agents to clear.

- Assess the tolerability of daptomycin in neutropenic patients.

- Assess and document adverse events and toxicity due to daptomycin.

OUTLINE: This is an open-label, pilot study.

Patients first receive standard treatment for gram-negative bacteria for 72 hours. If the patient is still febrile at 72 hours, daptomycin is administered.

Patients receive daptomycin IV over 30 minutes once daily. Patients who are afebrile, not neutropenic (absolute neutrophil count [ANC] > 500/mm³), and have no signs of infection after 72 hours of therapy may discontinue daptomycin. Patients who are afebrile and neutropenic (ANC < 500/mm³) after 72 hours of therapy continue to receive daptomycin until absolute neutrophil count (ANC) > 500/mm³ for 2 consecutive days. Patients who are febrile with or without continued neutropenia (ANC < 500/mm³) after 72 hours of therapy continue to receive daptomycin for up to 10-14 days in the absence of unacceptable toxicity.

PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.


Recruitment information / eligibility

Status Completed
Enrollment 54
Est. completion date October 2008
Est. primary completion date October 2008
Accepts healthy volunteers No
Gender All
Age group 18 Years to 99 Years
Eligibility DISEASE CHARACTERISTICS:

- Diagnosis of cancer

- Diagnosis of neutropenic fever

- Temperature > 38.3°C once OR = 38°C twice within 12 hours

- Absolute neutrophil count < 500/mm^³ and = 1 of the following:

- Mucositis

- Concurrent skin or soft tissue infection

- Indwelling catheter and/or suspected catheter infection

- Recent quinolone prophylaxis

- Positive blood cultures for gram-positive cocci before final identification or other documented gram-positive pathogen

- Colonization with ß-lactam resistant gram-positive organisms (commonly the nares or the skin)

- Hypotension, tachycardia, narrowed pulse pressures, tachypnea, or other signs of cardiovascular compromise

- Expected duration of neutropenia = 3 days

- No known infection with daptomycin-resistant organism or gram-negative organism and not yet meeting criteria for the addition of gram-positive antimicrobial therapy

- No suspected meningitis or osteomyelitis

- No documented or suspected gram-positive pneumonia

- No suspected or proven endocarditis

PATIENT CHARACTERISTICS:

- Eastern Cooperative Oncology Group (ECOG) performance status 0-2

- Life expectancy = 2 weeks

- Creatinine clearance = 50 mL/min

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective double-method contraception

- No known sensitivity to daptomycin or product excipients

- No history of or concurrent rhabdomyolysis

- No HIV positivity

- No psychiatric disorders that would preclude study compliance

- No signs or symptoms of myopathy with creatine phosphokinase (CPK) elevation > 1,000 U/L (5 times upper limit of normal [ULN])

- No CPK elevations > 10 times ULN in patients with no signs or symptoms of myopathy

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- At least 7 days since prior daptomycin or other antibiotic agents covering gram-positive organisms

- No concurrent hemodialysis or continuous ambulatory peritoneal dialysis

- No concurrent succinylcholine, ethanol, fludrocortisone, olanzapine, or pioglitazone

- No concurrent hydroxymethyl glutaryl (HMG) coenzyme A (HMG CoA) reductase inhibitors (e.g., lovastatin, simvastatin, atorvastatin)

- Concurrent therapy for gram-negative bacterial infection allowed

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Daptomycin
daptomycin 6 mg/kg over 30 minutes every 24 hours until patient is afebrile and ANC is >500 cells/mm^3.

Locations

Country Name City State
United States OHSU Knight Cancer Institute Portland Oregon

Sponsors (1)

Lead Sponsor Collaborator
OHSU Knight Cancer Institute

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants Who Became Afebrile Within 72 Hours of Starting Daptomycin. If after 72 hours of daptomycin treatment, the patient is afebrile and has absolute neutrophil count (ANC) >500 cells/mm^3 for 48 hours with no site of infection, negative cultures, and no clinical indications for therapy, the antibiotic regimen will be discontinued.
Complete Response: Resolution of fever and clinical signs/symptoms of infection.
Partial Response: Resolution of fever without resolution of clinical signs of infection.
Within 72 hours of starting daptomycin
See also
  Status Clinical Trial Phase
Completed NCT01828775 - Palliative Care Intervention in Improving Quality of Life, Psychological Distress, and Communication in Patients With Solid Tumors Receiving Treatment N/A
Terminated NCT01642342 - Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors Phase 1
Completed NCT00002950 - Topotecan Plus Sargramostim in Treating Patients With Advanced Cancer Phase 1/Phase 2
Completed NCT01705548 - Hypofractionated Stereotactic Radiosurgery in Treating Patients With Large Brain Metastasis N/A
Completed NCT02146222 - VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors Phase 1
Terminated NCT01602627 - Hsp90 Inhibitor AUY922 in Treating Older Patients With Advanced Solid Malignancies Phase 1
Completed NCT01191216 - 1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid Tumors Phase 1
Recruiting NCT01137825 - Registry of Older Patients With Cancer
Recruiting NCT00992303 - Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy and Healthy Participants
Completed NCT00949949 - Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy Phase 1
Completed NCT00924651 - Exercise in Lessening Fatigue Caused by Cancer in Patients Undergoing Chemotherapy Phase 3
Suspended NCT00935090 - 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer N/A
Withdrawn NCT00937417 - S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors Phase 1
Active, not recruiting NCT00710632 - Screening to Predict Weight Loss in Patients With Cancer N/A
Completed NCT00544596 - R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung Cancer Phase 1
Completed NCT00573690 - Sorafenib Combined With Cisplatin and Etoposide or Carboplatin and Pemetrexed in Treating Patients With Metastatic Solid Tumors Phase 1
Active, not recruiting NCT00436735 - Nelfinavir in Treating Patients With Metastatic, Refractory, or Recurrent Solid Tumors Phase 1
Completed NCT00352443 - S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma Phase 1
Completed NCT00128622 - Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer Phase 1
Completed NCT00121277 - Vorinostat and Capecitabine in Treating Patients With Metastatic or Unresectable Solid Tumors Phase 1